Market capitalization | $1.05b |
Enterprise Value | $844.11m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 328.45 |
P/S ratio (TTM) P/S ratio | 408.03 |
P/B ratio (TTM) P/B ratio | 5.22 |
Revenue (TTM) Revenue | $2.57m |
EBIT (operating result TTM) EBIT | $-60.51m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Silverback Therapeutics forecast:
4 Analysts have issued a Silverback Therapeutics forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2.57 2.57 |
-
|
|
Gross Profit | 2.39 2.39 |
241%
241%
|
|
EBITDA | -60 -60 |
22%
22%
|
EBIT (Operating Income) EBIT | -61 -61 |
24%
24%
|
Net Profit | -49 -49 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson on January 4, 2016 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Richard Lowenthal |
Employees | 26 |
Founded | 2015 |
Website | www.ars-pharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.